Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
High rate of improvement in serum matrix metalloproteinase-3 levels at 4 weeks predicts remission at 52 weeks in RA patients treated with adalimumab.
Hattori Y, Kojima T, Kaneko A, Kida D, Hirano Y, Fujibayashi T, Yabe Y, Oguchi T, Kanayama Y, Miyake H, Kato T, Takagi H, Hayashi M, Ito T, Shioura T, Takahashi N, Ishikawa H, Funahashi K, Ishiguro N. Hattori Y, et al. Among authors: shioura t. Mod Rheumatol. 2018 Jan;28(1):119-125. doi: 10.1080/14397595.2017.1317320. Epub 2017 May 2. Mod Rheumatol. 2018. PMID: 28463029
Study protocol of a multicenter registry of patients with rheumatoid arthritis starting biologic therapy in Japan: Tsurumai Biologics Communication Registry (TBCR) study.
Kojima T, Kaneko A, Hirano Y, Ishikawa H, Miyake H, Oguchi T, Takagi H, Yabe Y, Kato T, Ito T, Terabe K, Fukaya N, Kanayama Y, Shioura T, Funahashi K, Hayashi M, Kato D, Matsubara H, Fujibayashi T, Kojima M, Ishiguro N; TBC. Kojima T, et al. Among authors: shioura t. Mod Rheumatol. 2012 Jun;22(3):339-45. doi: 10.1007/s10165-011-0518-4. Epub 2011 Sep 3. Mod Rheumatol. 2012. PMID: 21892671
Early aggressive intervention with tocilizumab for rheumatoid arthritis increases remission rate defined using a Boolean approach in clinical practice.
Kojima T, Kaneko A, Hirano Y, Ishikawa H, Miyake H, Takagi H, Yabe Y, Kato T, Terabe K, Fukaya N, Tsuchiya H, Shioura T, Funahashi K, Hayashi M, Kato D, Matsubara H, Ishiguro N. Kojima T, et al. Among authors: shioura t. Mod Rheumatol. 2012 Jun;22(3):370-5. doi: 10.1007/s10165-011-0528-2. Epub 2011 Sep 20. Mod Rheumatol. 2012. PMID: 21931942
Monitoring C-reactive protein levels to predict favourable clinical outcomes from tocilizumab treatment in patients with rheumatoid arthritis.
Kojima T, Yabe Y, Kaneko A, Hirano Y, Ishikawa H, Hayashi M, Miyake H, Takagi H, Kato T, Terabe K, Wanatabe T, Tsuchiya H, Kida D, Shioura T, Funahashi K, Kato D, Matsubara H, Takahashi N, Hattori Y, Asai N, Ishiguro N. Kojima T, et al. Among authors: shioura t. Mod Rheumatol. 2013 Sep;23(5):977-85. doi: 10.1007/s10165-012-0782-y. Epub 2012 Oct 26. Mod Rheumatol. 2013. PMID: 23099471
Longterm retention rate and risk factor for discontinuation due to insufficient efficacy and adverse events in Japanese patients with rheumatoid arthritis receiving etanercept therapy.
Matsubara H, Kojima T, Kaneko A, Hirano Y, Ishikawa H, Hattori Y, Miyake H, Oguchi T, Takagi H, Yabe Y, Kato T, Ito T, Fukaya N, Kanayama Y, Shioura T, Hayashi M, Fujibayashi T, Takahashi N, Funahashi K, Kato D, Hanabayashi M, Terabe K, Ishiguro N. Matsubara H, et al. Among authors: shioura t. J Rheumatol. 2014 Aug;41(8):1583-9. doi: 10.3899/jrheum.130901. Epub 2014 Jul 15. J Rheumatol. 2014. PMID: 25028370
Drug retention rates of second biologic agents after switching from tumor necrosis factor inhibitors for rheumatoid arthritis in Japanese patients on low-dose methotrexate or without methotrexate.
Kobayakawa T, Kojima T, Takahashi N, Hayashi M, Yabe Y, Kaneko A, Shioura T, Saito K, Hirano Y, Kanayama Y, Miyake H, Asai N, Funahashi K, Hirabara S, Hanabayashi M, Asai S, Ishiguro N. Kobayakawa T, et al. Among authors: shioura t. Mod Rheumatol. 2015 Mar;25(2):251-6. doi: 10.3109/14397595.2014.953668. Epub 2014 Sep 11. Mod Rheumatol. 2015. PMID: 25211402
18 results